Joanna J. Phillips

Profesor

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (25)

Year:

2026

Year:

2025

Advances in digital pathology and machine learning have the potential to revolutionize diagnostic neuropathology. Current brain tumor models are typically trained and validated using morphologic features from a single hematoxylin and eosin (H&E)-stained slide per patient. Yet, brain tumors such as diffuse glioma are known for their epigenetic, genetic, and transcriptional heterogeneity within an individual patient. The impact of this heterogeneity on model accuracy and development is unknown. To quantitatively investigate morphologic intratumoral heterogeneity in glioblastoma (GBM), we acquired 92 regionally distinct samples representing maximal tumor sampling across 10 patients with isocitrate dehydrogenase-wildtype GBM and quantified cell density, nucleus area, and nucleus circularity from whole-slide scanned images of H&E-stained slides. All 3 parameters exhibited significant morphologic variation between tumors from different patients and within a given tumor. To identify potential drivers of this variation, tumor-level and sample-level mutation profiling was performed. Mutations in tumor protein 53 both at the tumor level and the sample level had larger nuclear area and decreased nuclear circularity. Morphological features were not associated with regional location within the tumor. Accurate and robust H&E-based models to improve diagnosis and disease prognostication may require training sets that incorporate multiple spatially distinct samples per patient.

Year:

2025

Purpose: Pediatric recurrent medulloblastoma and atypical teratoid/rhabdoid tumor (ATRT) are largely incurable and warrant novel therapies. PNOC005 is a phase I clinical trial investigating the safety and tolerability of intratumoral or intrathecal administration of oncolytic measles virus (MV-NIS) in children and young adults with recurrent medulloblastoma or ATRT. Patients and Methods: We investigated (i) the safety of a measles virus variant, MV-NIS, in a pediatric phase I study and (ii) the mechanisms of MV-NIS and the potential benefit of combination with immune checkpoint inhibition (ICI). Pediatric patients with recurrent medulloblastoma or ATRT were treated with intratumoral injections for local recurrence or via lumbar puncture for disseminated recurrence. We evaluated local immune responses to MV-NIS with and without ICI via single-cell and bulk RNA sequencing in an intracranial, immunocompetent, syngeneic murine model. Results: MV-NIS given intratumorally or via repeat intrathecal dosing was safe. MV-NIS prolonged survival in murine models but did not demonstrate an additive benefit with ICI. No changes in tumor-infiltrating immune cell composition or activation were observed in response to MV-NIS treatment; however, MV-NIS induced local expression of neutralizing antibodies, complement cascade, and phagocytosis-related genes. Conclusions: This is the first trial investigating intratumoral as well as repeated intrathecal delivery of MV-NIS in children with medulloblastoma and ATRT. We show that the therapy is safe and well tolerated, with minimal adverse effects. Immune markers and biological correlates preliminarily indicate antiviral effects in tumors.

Year:

2025

Oligodendrogliomas are initially slow-growing brain tumors that are prone to malignant transformation despite surgery and cytotoxic therapy. Understanding of oligodendroglioma evolution and new treatments for patients have been encumbered by a paucity of patient-matched newly diagnosed and recurrent tumor samples for multiplatform analyses, and by a lack of preclinical models for interrogation of therapeutic vulnerabilities that drive oligodendroglioma growth. Here we integrate spatial and functional analyses of tumor samples and patient-derived organoid co-cultures to show that synaptic connectivity is a hallmark of oligodendroglioma evolution and recurrence. We find that patient-matched recurrent oligodendrogliomas are enriched in synaptic gene expression programs irrespective of previous therapy or histologic grade. Analyses of spatial, single-cell, and clinical data reveal epigenetic misactivation of synaptic genes that are concentrated in regions of cortical infiltration and can be used to predict eventual oligodendroglioma recurrence. To translate these findings to patients, we show that local field potentials from tumor-infiltrated cortex at the time of resection and neuronal hyperexcitability and synchrony in patient-derived organoid co-cultures are associated with oligodendroglioma proliferation and recurrence. In preclinical models, we find that neurophysiologic drugs block oligodendroglioma growth and pathologic electrophysiology. These results elucidate mechanisms underlying oligodendroglioma evolution from an indolent tumor to a fatal disease and shed light on new biomarkers and new treatments for patients.

Year:

2025

Deregulation of neuroblastoma-derived myc (N-myc) is a leading cause of malignant brain tumors in children. To target N-myc-driven medulloblastoma, most research has focused on identifying genomic alterations or on the analysis of the medulloblastoma transcriptome. Here, we have broadly characterized the translatome of medulloblastoma and shown that N-myc unexpectedly drives selective translation of transcripts that promote protein homeostasis. Cancer cells are constantly exposed to proteotoxic stress associated with alterations in protein production or folding. It remains poorly understood how cancers cope with proteotoxic stress to promote their growth. Here, our data revealed that N-myc regulates the expression of specific components (∼5%) of the protein folding machinery at the translational level through the major cap binding protein, eukaryotic initiation factor eIF4E. Reducing eIF4E levels in mouse models of medulloblastoma blocked tumorigenesis. Importantly, targeting Hsp70, a protein folding chaperone translationally regulated by N-myc, suppressed tumor growth in mouse and human medulloblastoma xenograft models. These findings reveal a previously hidden molecular program that promotes medulloblastoma formation and identify new therapies that may have impact in the clinic. Significance: Translatome analysis in medulloblastoma shows that N-myc drives selective translation of transcripts that promote protein homeostasis and that represent new therapeutic vulnerabilities.

Year:

2025

Supplementary Fig. 6. WHO grade 3 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 is expressed in and out of the perivascular niche, and colocalizes with mural cells in the perivascular niche, in meningiomas with WHO grade 3 histology. SF numbers indicate individual meningiomas. Representative of n=10 WHO grade 3 meningiomas. WHO grade defined using histological criteria. Scale bars, 10µm.

Year:

2024

Supplementary Table S1. Cell cluster marker genes from single-cell RNA sequencing of human meningiomas with loss of chromosome 22q. Supplementary Table S2. Cell cluster marker genes from single-cell RNA sequencing of dog meningiomas. Supplementary Table S3. RNA sequencing differential expression analyses across recurrent versus primary human meningiomas. Supplementary Table S4. Antibodies for multiplexed sequential immunofluorescence. Supplementary Table S5. Cell cluster marker genes from single-cell RNA sequencing of human cells from meningioma xenografts. Supplementary Table S6. Cell cluster marker genes from single-cell RNA sequencing of mouse cells from meningioma xenografts.

Year:

2024

Supplementary Fig. 5. WHO grade 2 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is primarily restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 2 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 2 meningiomas. Scale bars, 10µm.

Year:

2024

Supplementary Fig. 4. WHO grade 1 meningioma immunofluorescence microscopy for NOTCH3 and the mural cell marker SMA. NOTCH3 expression is restricted to the perivascular niche and colocalizes with mural cells in meningiomas with WHO grade 1 histology. SF numbers indicate individual meningiomas. WHO grade defined using histological criteria. Representative of n=10 WHO grade 1 meningiomas. Scale bars, 10µm.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2022

Collaborators (35)

Aaron Diaz

University of California, San Francisco

UNITED STATES
View details

Jennie W Taylor

University of California

UNITED STATES
View details

Ali Nabavizadeh

University of Pennsylvania

UNITED STATES
View details

Aparna Bhaduri

Assistant Professor

University of California, Los Angeles

UNITED STATES
View details

Davide Ruggero

Professor

University of California

UNITED STATES
View details

Brisa Palikuqi

Assistant Professor

Yale University

UNITED STATES
View details

Craig Horbinski

Northwestern University

UNITED STATES
View details

Elizabeth George

University of California, San Francisco

UNITED STATES
View details

Peter J. Dickinson

-

UNITED STATES
View details

Noriyuki Kasahara

Professor

University of California, San Francisco

UNITED STATES
View details

Ophir Klein

Cedars-Sinai Medical Center

UNITED STATES
View details

Robert Wechsler-Reya

Professor

Columbia University Irving Medical Center

UNITED STATES
View details

Alan Ashworth

University of California, San Francisco

UNITED STATES
View details

Shawn L. Hervey‐Jumper

Professor

University of California, San Francisco

UNITED STATES
View details

Stephen T. Magill

Assistant Professor

Northwestern University

UNITED STATES
View details

Amy B. Heimberger

Professor

Northwestern University

UNITED STATES
View details

Calixto-Hope G Lucas

Johns Hopkins University School of Medicine

UNITED STATES
View details

Annette M. Molinaro

University of California

UNITED STATES
View details

Sean Bendall

Stanford University School of Medicine

UNITED STATES
View details

Christine M. Toedebusch

University of California

UNITED STATES
View details

Mohamed Abdelbaki

Washington University

UNITED STATES
View details

Sabine Mueller

Adjunt Associate Professor

University of California

UNITED STATES
View details

Duygu Kuzuoglu Ozturk

Assistant Prof

Sabancı University

TURKEY
View details

Arie Perry

University of California, San Francisco

UNITED STATES
View details

Nalin Gupta

Professor

University of California, San Francisco

UNITED STATES
View details

Erin Crotty

Assistant Professor/Principal Investigator

Seattle Children's Hospital

UNITED STATES
View details

Bohyeon Yu

University of California, San Francisco

UNITED STATES
View details

Jason E. Gestwicki

Professor

University of California, San Francisco

UNITED STATES
View details

David R Raleigh

University of California, San Francisco

UNITED STATES
View details

Michael Prados

University of California

UNITED STATES
View details

Albert Tsai

Assistant Professor

Stanford University

UNITED STATES
View details

Miller Huang

Assistant Professor

University of Southern California

UNITED STATES
View details

Richard Drake

Professor and Endowed Chair in Proteomics

Medical University of South Carolina

UNITED STATES
View details

Harish Vasudevan

University of California, San Francisco

UNITED STATES
View details

William A. Weiss

Director of outpatient child neurology

University of California

UNITED STATES
View details